e72bd7b6-c350-4f96-a633-8bf86079f57c
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 37.1416837782341
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.670
- ANGIOGENESIS+0.540
- PANCREAS_BETA_CELLS+0.460
- UV_RESPONSE_DN+0.440
- MYOGENESIS+0.430
- HEDGEHOG_SIGNALING+0.410
- INFLAMMATORY_RESPONSE+0.390
- APICAL_JUNCTION+0.340
- KRAS_SIGNALING_UP+0.330
- TGF_BETA_SIGNALING+0.330
Top 10 suppressed
- MYC_TARGETS_V2-0.650
- OXIDATIVE_PHOSPHORYLATION-0.640
- MYC_TARGETS_V1-0.540
- E2F_TARGETS-0.440
- MTORC1_SIGNALING-0.440
- FATTY_ACID_METABOLISM-0.410
- PEROXISOME-0.400
- CHOLESTEROL_HOMEOSTASIS-0.390
- DNA_REPAIR-0.350
- G2M_CHECKPOINT-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR25043620 | — | — | 0.951 |
| 2 | 4108a871-c064-4537-9331-e59798d7d492 | — | — | 0.951 |
| 3 | a307b24f-4caa-403a-8313-2a4604f2079a | — | — | 0.942 |
| 4 | 1b5aacb8-0e2e-4888-bc61-48c4aa4d4684 | — | — | 0.938 |
| 5 | 07234abb-aa8c-434f-898c-6f7ba28c5850 | — | — | 0.925 |
| 6 | 17d3d480-5503-419e-92cd-cbc7db9659d2 | — | — | 0.917 |
| 7 | TCGA-CV-6934-01A-11R-1915-07 | — | — | 0.911 |
| 8 | 21196229-e39e-4846-be58-a1055b3ae50e | — | — | 0.911 |
| 9 | TCGA-CN-4728-01A-01R-1436-07 | — | — | 0.908 |
| 10 | TCGA-MP-A4TK-01A-11R-A24X-07 | — | cohortA1 | 0.908 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.670 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.540 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.460 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.440 | Inavolisib | — uncovered |
| MYOGENESIS | 0.430 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.410 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.340 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.330 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.330 | Inavolisib | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.310 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.280 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.260 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.250 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.210 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |